Clinical Trial Detail

NCT ID NCT03493945
Title Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1).
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

prostate cancer

Advanced Solid Tumor

Therapies

ALT-803 + Epacadostat + FPV-Brachyury + M7824 + MVA-BN-Brachyury

FPV-Brachyury + M7824 + MVA-BN-Brachyury

ALT-803 + FPV-Brachyury + M7824 + MVA-BN-Brachyury

ALT-803 + M7824

Age Groups:

No variant requirements are available.